Combinations of plant polyphenols & anti-cancer molecules: A novel treatment strategy for cancer chemotherapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 281-295

  Mohan, Aarti ^a   Narayanan, Shridhar ^b   Sethuraman, Swaminathan ^a   Krishnan, Uma Maheswari ^a  

^a SASTRA UNIVERSITY   (India)

^b Orchid Chemicals and Pharmaceuticals Ltd   (India)

Author keywords

5 fluorouracil; Anti inflammatory; Anti oxidant; Ara C; Cancer; Chemotherapy; Combination therapy; Curcumin; Cyclophosphamide; Doxorubicin; Flavonoids; NF B; Polyphenols; Resveratrol; Tea catechins

Indexed keywords

ANTINEOPLASTIC AGENT; APIGENIN; ASPARAGINASE MACROGOL; CHLORAMBUCIL; CISPLATIN; CURCUMIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; FLUOROURACIL; GEMCITABINE; GENISTEIN; HESPERETIN; IRINOTECAN; MERIVA; METHOTREXATE; MITOMYCIN; NARINGENIN; OXALIPLATIN; PACLITAXEL; PEGINTERFERON ALPHA2B; PLANT MEDICINAL PRODUCT; PREDNISONE; QUERCETIN; RESVERATROL; RUTOSIDE; SILYMARIN; TOFACITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALOPECIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE DISEASE; BRAIN DISEASE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; CELL DEATH; CHEMOPROPHYLAXIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG UPTAKE; FATIGUE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOTHERAPY; INCIDENCE; LIVER CANCER; MULTIPLE CYCLE TREATMENT; NANOTECHNOLOGY; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PROSTATE CANCER; PROSTATECTOMY; PSYCHOSOCIAL DISORDER; REVIEW; SOLID TUMOR; STOMATITIS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOPLASMS; PLANTS; POLYPHENOLS;

EID: 84876129955     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520611313020015     Document Type: Review

References (162)

1. de Vita Jr., V.T.; Chu, E. A history of cancer chemotherapy. Cancer Res., 2008, 68(21), 8643-8653.
2. J.M. Vose, B.K. Link, M.L. Grossbard, M. Czuczman, A. Grillo-Lopez, P. Gilman, A. Lowe, L.A. Kunkel, and R.I. Fisher. Phase II Study of Rituximab in Combination With CHOP Chemotherapy in Patients With Previously Untreated, Aggressive Non-Hodgkin's Lymphoma. J. Clin. Oncol., 2001, 19(2), 389-397.
3. Sun, X.; Lin, D.; Wu, W.; Lv, Z. Translational chinese medicine: a way for development of traditional chinese medicine. Chinese Medicine, 2011, 2, 186-190.
4. Johnson, J.J.; Bailey, H.H.; Mukhtar, H. Green tea polyphenols for prostate cancer chemoprevention: A translational perspective. Phytomedicine, 2010, 17(1), 3-13.
5. Jaiswal, A.S.; Marlow, B.P.; Gupta, N.; Narayan, S. Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 2002, 21(55), 8414-8427.
6. Saha, A.; Kuzuhara, T.; Echigo, N.; Suganuma, M.; Fujiki H. New role of (-)-epicatechin in enhancing the induction of growth inhibition and apoptosis in human lung cancer cells by curcumin. Cancer Prev. Res., 2010, 3(8), 953-962.
7. Cherng, J.M.; Shieh, D.E.; Chiang, W.; Chang M-Y.; Chiang L-C. Chemopreventive effects of minor dietary constituents in common foods on human cancer cells. Biosc. Biotechnol. Biochem., 2007, 71(6), 1500-1504.
8. Yao, L.H.; Jiang, Y.M.; Shi, J.; Tomas-Barberan, F.A.; Datta, N.; Singanusong, R.; Chen, S.S. Flavonoids in food and their health benefits. Plant Foods Hum. Nutr., 2004, 59(3), 113-122.
9. Nijveldt, R.J.; van Nood, E.; van Hoorn, D.E.C.; Boelens, P.G.; van Norren, K.; van Leeuwen, P.A.M. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr., 2001, 74(4), 418-425.
10. Scripture, C.D.; Figg, W.D. Drug interactions in cancer therapy. Nat. Rev. Cancer, 2006, 6(7), 546-558.
11. Saldanha, S.N.; Tollefsbol, T.O. The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. J. Oncol., 2012, 2012, Doi:10.1155/2012/192464.
12. Russo, M.; Spagnuolo, C.; Volpe, S.; Mupo, A.; Tedesco, I.; Russo, G.L. Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. Br. J. Cancer, 2010, 103(5), 642-648.
13. Garg, A.K.; Buchholz, T.A.; Aggarwal, B.B. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid. Redox Signal., 2005, 7(11-12), 1630-1647.
14. Shukla Y.; George, J. Combinatorial strategies employing nutraceuticals for cancer development. Ann. N.Y. Acad. Sci., 2011, 1229, 162-175.
15. Goodman, L.S.; Wintrobe, M.M.; Dameshek, W.; Goodman, M.J.; Gilman, A.; McLennan, M.T. Nitrogen mustard therapy: use of methyl-bis (β-chloroethyl) amine hydrochloride and tris (β-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. J. Am. Med. Assoc., 1946, 132, 126-132.
16. Hesketh, P.J.; Batchelor, D.; Golant, M.; Lyman, G.H.; Rhodes, N.; Yardley, D. Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer, 2004, 12(8), 543-549.
17. Quasthoff, S.; Hartung, H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol., 2002, 249(1), 9-17.
18. Sitzia, J.; Huggins, L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract., 1998, 6(1), 13-21.
19. Tierney, A.J.; Leonard, R.C.F.; Taylor, J.; Closs, S.J.; Chetty, U.; Rodger, A. Side effects expected and experienced by women receiving chemotherapy for breast cancer. BMJ, 1991, 302(6771), 272.
20. Broeckel, J.A.; Jacobsen, P.B.; Horton, J.; Balducci, L.; Lyman, G.H. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J. Clin. Oncol., 1998, 16(5), 1689-1696.
21. Schnell, F.M. Chemotherapy induced nausea and vomiting: the importance of acute anti-emetic control. Oncologist, 2003, 8(2), 187-198.
22. Aapro, M.; Bowler, P. 5-Hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis. Cancer, 2005, 104(1), 1-13.
23. Chi, K.H.; Chen, C.H.; Chan, W.K.; Chow, K. C.; Chen, S.Y.; Yen, S.H.; Chao, J.Y.; Chang, C.Y.; Chen, K.Y. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J. Clin. Oncol., 1995, 13(10), 2620-2628.
24. Spielberger, R.; Stiff, P.; Bensinger, W.; Gentile, T.; Weisdorf, D.; Kewalramani, T.; Shea, T.; Yanovich, S.; Hansen, K.; Noga, S.; McCarty, J.; LeMaistre, C.F.; Sung, E.C.; Blazar, B.R.; Elhardt, D.; Chen, M.G.; Emmanouilides, C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med., 2004, 351(25), 2590-2598.
25. Crawford, J.; Dale, D.C.; Lyman, G.H. Chemotherapy induced neutropenia- risks, consequences and new directions for its management. Cancer, 2004, 100(2), 228-237.
26. Kalyanaraman, B.; Joseph, J.; Kalivendi, S.; Wang, S.; Konorev, E.; Kotamraju, S. Doxorubicin-induced apoptosis: Implications in cardiotoxicity. Mol. Cell. Biochem., 2002, 234-235(1-2), 119-124.
27. Teraoka, K.; Hirano, M.; Yamaguchi, K.; Yamashina, A. Progressive cardiac dysfunction in adriamycin-induced cardiomyopathy rats. Eur. J. Heart. Fail., 2000, 2(4), 373-378.
28. Okuda, S.; Oh, Y.; Tsuruda, H.; Onoyama, K.; Fujimi, S.; Fujishima, M. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int., 1986, 29(2), 502-510.
29. van Norren, K.; van Helvoort, A.; Argilés, J.M.; van Tuijl, S.; Arts, K.; Gorselink, M.; Laviano, A.; Kegler, D.; Haagsman, H.P.; van der Beek, E.M. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br. J. Cancer., 2009, 100(2), 311-314.
30. Ling, B.; Authier, N.; Balayssac, D.; Eschalier, A.; Coudore, F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain, 2007, 128(3), 225-234.
31. Hussein, M.A.; Wood, L.; Hsi, E.; Srkalovic, G.; Karam, M.; Elson, P.; Bukowski, R.M. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer, 2002, 95(10), 2160-2168.
32. O'Brien, M.E.R.; Wigler, N.; Inbar, M.; Rosso, R.; Grischke, E.; Santoro, A.; Catane, R.; Kieback, D.G.; Tomczack, P.; Ackland, S.P.; Orlandi, F.; Mellars, L.; Alland, L.; Tendler, C. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol., 2004, 15(3), 440-449.
33. Batist, G.; Gelmon, K.A.; Chi, K.N.; Miller, W.H. Jr.; Chia, S.K.; Mayer, L.D.; Swenson, C.E.; Janoff, A.S.; Louie, A.C. Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer. Res., 2009, 15(2), 692-700.
34. Patil, Y.B.; Swaminathan, S.K.; Sadhukha, T.; Ma, L.; Panyam, J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J.Control. Release, 2009, 136(1), 21-29.
35. Chen, B.; Lai, B.; Cheng, J.; Xia, G.; Gao, F.; Xu, W.; Ding, J.; Gao, C.; Sun, X.; Xu, C.; Chen, W.; Chen, N.; Liu, L.; Li, X.; Wang, X. Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo. Int. J. Nanomedicine, 2009, 4, 201-208.
36. Patil, Y.B.; Swaminathan, S.K.; Sadhukha, T.; Ma, L.; Panyam, J. The use of nanoparticle mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials, 2010, 31(2), 358-365.
37. Chrastina, A.; Massey, K.A.; Schnitzer, J.E. Overcoming in vivo barriers to targeted nanodelivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2011, 3(4), 421-437.
38. Hu, C-M. J.; Zhang, L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug Metab., 2009, 10(8), 836-841.
39. Dienstmann, R.; Markman, B.; Tabernero, J. Application of monoclonal antibodies as cancer therapy in solid tumors. Curr. Clin. Pharmacol, 2012, 7(2), 137-145.
40. Oldham, R.K.; Dillman, R.O. Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress. J. Clin Oncol., 2008, 26(11), 1774-1777.
41. Kantoff, P.W.; Schuetz, T.J.; Blumenstein, B.A.; Glode, L.M.; Bilhartz, D.L.; Wyand, M.; Manson, K.; Panicali, D.L.; Laus, R.; Schlom, J.; Dahut, W.L.; Arlen, P.M.; Gulley, J.L.; Godfrey, W.R. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol., 2010, 28(7), 1099-1105.
42. Cheever, M.A.; Higano, C.S. PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine. Clin. Cancer Res., 2011, 17(11), 3520-3526.
43. Miyazaki, A.; Kobayashi, J.; Torigoe, T.; Hirohashi, Y.; Yamamoto, T, Yamaguchi, A.; Asanuma, H.; Takahashi, A.; Michifuri, Y.; Nakamori, K.; Nagai, I.; Sato, N.; Hiratsuka, H. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci., 2011, 102(2), 324-329.
44. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; Korbelik, M. Photodynamic therapy of cancer: an update. C.A. Cancer J. Clin., 2011, 61(4), 250-81.
45. Karakullukcu, B.; van Oudenaarde, K.; Copper, M.P.; Klop, W.M.; van Veen, R.; Wildeman, M.; Bing Tan, I. Photodynamic therapy of early stage oral cavity and oropharynx neoplasms: an outcome analysis of 170 patients. Eur. Arch. Otorhinolaryingol., 2011, 268(2), 281-288.
46. Ramos, S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol. Nutr. Food Res., 2008, 52(5), 507-526.
47. Beecher, G.R. Overview of dietary flavonoids: nomenclature, occurrence and intake. J. Nutr., 2003, 133(10), 3248S-3254S.
48. Havsteen, B.H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther., 2002, 96(2-3), 67-202.
49. Garg, A.; Aggarwal, B.B. Nuclear transcription factor κB as a target for cancer drug development. Leukemia, 2002, 16(6), 1053-1068.
50. Bharti, A.C.; Aggarwal, B.B. Chemopreventive agents induce suppression of nuclear factor-κB leading to chemosensitization. Ann. N.Y. Acad. Sci., 2002, 973, 392-395.
51. Li, Y.; Sarkar, F.H. Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res., 2002, 8(7), 2369-2377.
52. Wang, C-Z.; Mehendale, S.R.; Yuan, C-S. Commonly Used Antioxidant Botanicals: Active Constituents and their Potential Role in Cardiovascular Illness. Am. J. Chin. Med., 2007, 35(4), 543-558.
53. Walle, T.; Hsieh, F.; Delegge, M.H.; Oatis, J.E. Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos., 2004, 32(12), 1377-1382.
54. Cottart, C-H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J.L. Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res., 2010, 54(1), 7-16.
55. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of Curcumin: Problems and Promises. Mol. Pharm., 2007, 4(6), 807-818.
56. Sharma, R.A.; Steward, W.P.; Gescher, A.J. In: Advances in Experimental Medicine and Biology; Bharat. B. Aggarwal; Young Joon Surh; Shishir Shishodia. Ed.; Springer Science+ Business Media, LLC: New York, 2007; Vol. 595, pp. 453-470.
57. Zhu, M.; Chen, Y.; Li, R.C. Oral absorption and bioavailability of tea catechins. Planta Med., 2000, 66(5), 444-447.
58. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr., 2005, 81(1 Suppl), 230S-242S.
59. Takano, F.; Tanaka, T.; Aoi, J.; Yahaqi, N.; Fushiya, S. Protective effect of (+)-catechin against 5-fluorouracil-induced myelosuppression in mice. Toxicology, 2004, 201(1-3), 133-142.
60. Babich, H.; Krupka, M.E.; Nissim, H.A.; Zuckerbraun, H.L. Differential in vitro cytotoxicity of (-)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity. Toxicol. In Vitro, 2005, 19(2), 231-242.
61. Lee, J-C.; Kim, J.; Park, J-K.; Chung, G.H.; Jang, Y.S. The antioxidant, rather than prooxidant, activities of quercetin on normal cells: quercetin protects mouse thymocytes from glucose oxidase-mediated apoptosis. Exp. Cell. Res., 2003, 291(2), 386-397.
62. Aggarwal, B.B.; Shishodia, S. Resveratrol in health and disease, CRC Press: Boca Raton, 2006.
63. Leonard, S.S.; Xia, C.; Jiang, B.H.; Stinefelt, B.; Klandorf, H.; Harris, G.K.; Shi, X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun., 2003, 309(4), 1017-1026.
64. Miksits, M.; Wlcek, K.; Svoboda, M.; Kunert, O.; Haslinger, E.; Thalhammer, T.; Szekeres, T.; Jager, W. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta. Med., 2009, 75(11), 1227-1230.
65. Calamini, B.; Ratia, K.; Malkowski, M.G.; Cuendet, M.; Pezutto, J.M.; Santasiero, B.D.; Mesecar, A.D. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J., 2010, 429(2), 273-282.
66. Woo, J.H.; Kim, Y.H.; Choi, Y.J.; Kim, D.G.; Lee, K.S.; Bae, J.H.; Min, D.S.; Chang, J.S.; Jeong, Y.J.; Lee, Y.H.; Park, J.W.; Kwon, T.K. Molecular mechanisms of curcumin induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species downregulation of Bcl-xl and IAP, release of cytochrome-c and inhibition of Akt. Carcinogenesis, 2003, 24(7), 1199-1208.
67. Anto, R.J.; Mukhopadhyay, A.; Denning, K.; Aggarwal, B.B. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome C release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis, 2002, 23(1), 143-150.
68. Thayyullathil, F.; Chattoth, S.; Hago, A.; Patel, M.; Galadari, S. Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic. Biol. Med., 2008, 45(10), 1403-1412.
69. Mukhopadhyay, A.; Banerjee, S.; Stafford, L.J.; Xia, C.; Liu, M.; Aggarwal, B.B. Curcumin induced suppression of cell proliferation correlates with downregulation of cyclin D1 expression and CDK4 mediated restinoblastoma protein phosphorylation. Oncogene, 2002, 21(57), 8852-8861.
70. Ravindranath, V.; Chandrasekhara, N. Absorption and tissue distribution of curcumin in rats. Toxicology, 1980, 16(3), 259-265.
71. Suresh, D.; Srinivasan, K. Tissue distribution & elimination of capsaicin, piperine & curcumin following oral intake in rats. Indian J. Med. Res., 2010, 131, 682-691.
72. Atten, M.J.; Attar, B.M.; Milson, T.; Holian, O. Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem. Pharmacol., 2001, 62(10), 1423-1432.
73. Wolter, F.; Akoglu, B.; Clausnitzer, A.; Stein, J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol- induced cell cycle arrest in colon cancer cell lines. J. Nutr., 2001, 131(8), 2197-2203.
74. Holian, O.; Wahid, S.; Atten, M.J.; Attar, B.M. Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 282(5), G809-G816.
75. Joe, A.K.; Liu, H.; Suzui, M.; Vural, M.E.; Xiao, D.; Weinstein, I.B. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res., 2002, 8(3), 893-903.
76. Bai, Y.; Mao, Q-Q.; Qin, J.; Zheng, X.Y.; Wang, Y.B.; Yang, K.; Shen H.F.; Xie, L.P. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci., 2010, 101(2), 488-493.
77. Vergara, D.; Valente, C.M.; Tinelli, A.; Carlo Siciliano, C.; Lorusso, V.; Acierno, R.; Giovinazzo, G.; Santino, A.; Storelli, C.; Maffia, M. Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Lett, 2011, 310(1), 1-8.
78. Lee, M-F.; Pan, M-H.; Chiou, Y-S.; Cheng, A-C.; Huang, H. Resveratrol Modulates MED28 (Magicin/EG-1) Expression and Inhibits Epidermal Growth Factor (EGF)-Induced Migration in MDA-MB-231 Human Breast Cancer Cells. J. Agric. Food Chem., 2011, 59 (21), 11853-11861.
79. Ko, Y-C.; Chang, C-L.; Chien, H-F.; Wu, C-H.; Lin, L-L. Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells. Cancer Lett, 2011, 309(1), 46-53.
80. Plummer, S.M.; Holloway, K.A.; Manson, M.M.; Munks, R.J.; Kaptein, A.; Farrow, S.; Howells, L. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/IKK signalling complex. Oncogene, 1999, 18(44), 6013-6020.
81. Ranjan, D.; Chen, C.; Johnston, T.D.; Jeon, H.; Nagabhushan, M. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFκB activation, and IL-2 signaling. J. Surg. Res., 2004, 121(2), 171-177.
82. LoTempio, M.M.; Veena, M.S.; Steele, H.L.; Ramamurthy, B.; Ramalingam, T.S.; Cohen, A.N.; Chakrabarti, R.; Srivatsan, E.S.; Wang, M.B. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin. Cancer Res., 2005, 11(19), 6994-7002.
83. Yadav, V.S.; Mishra, K.P.; Singh, D.P. Curcumin inhibits Jurkat cell proliferation by inducing apoptosis via activation-induced cell death. Biomed. Pharmacother., 2010, Published on Sept 20, 2010. doi: 10.1016/jbiopha.2010.08.001.
84. Banerjee, M.; Singh, P.; Panda, D. Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS Journal, 2010, 277(16), 3437-3448.
85. Phan, T.A.; Yu, X.M.; Kunnimalaiyaan, M.; Chen, H. Antiproliferative effect of chrysin on anaplastic thyroid cancer. J. Surg. Res., 2011, 170(1), 84-88.
86. Li, X.; Wang, J-N.; Huang, J-M.; Xiong, X.K.; Chen, M.F.; Ong, C.N.; Shen, H.M.; Yang, X.F. Chrysin promotes tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced apoptosis in human cancer cell lines. Toxicol. In Vitro., 2011, 25(3), 630-635.
87. You, B.R.; Moon, H.J.; Han, Y.H.; Park, W.H. Gallic acid inhibits the growth of HeLa cervical cancer cells via apoptosis and/or necrosis. Food Chem. Toxicol., 2010, 48(5), 1334-1340.
88. Choi, K-C.; Lee, Y-H.; Jung, M.G.; Kwon, S.H.; Kim, M.J.; Jun, W.J.; Lee, J.; Lee, J.M.; Yoon, H.G. Gallic acid suppresses lipopolysaccharide-induced nuclear factor-κB signaling by preventing RelA acetylation in A549 lung cancer cells. Mol. Cancer Res., 2009, 7(12), 2011-2021.
89. Takahashi, H.; Chen, M.C.; Pham, H.; Angst, E.; King, J.C.; Park, J.; Brovman, E.Y.; Ishiquoro, H.; Harris, D.M.; Reber, H.A.; Hines, O.J.; Gukovskaya, A.S.; Go, V.L.; Eibl, G. Baicalein, a component of Scutellaria baicalensis induces apoptosis by Mcl-1 downregulation in human pancreatic cells. Biochim. Biophys. Acta, 2011,1813(8), 1465-1474.
90. Chou, D-S.; Hsiao, G.; Lai, Y-A.; Tsai, Y.J.; Sheu, J.R. Baicalein induces proliferation inhibition in B16F10 melanoma cells by generating reactive oxygen species via 12-lipoxygenase, Free. Radic. Biol. Med., 2009, 46(8), 1197-1203.
91. Qi, W.; Weber, C.R.; Wasland, K.; Savkovic, S.D. Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer, 2011, 11, 219.
92. Luo, H.; Rankin, G.O.; Li, Z.; DePriest, L.; Chen, Y.C. Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. Food Chem., 2011, 128(2), 513-519.
93. Huang, W-W.; Chiu, Y-J.; Fan, M-J.; Lu, H-F.; Yeh, H-F.; Li, K-H.; Chen, P-Y.; Chung J-G.; Yang, J-S. Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma U-2 OS cells. Mol. Nutr. Food Res., 2010, 54(11), 1585-1595.
94. Chan M.M.; Fong, D. In: Drug Resistance in Cancer Cells; Kapil Mehta, Zahid.H. Siddik; Ed.; Springer Science+Business Media, LLC: New York, 2009; pp. 315-342.
95. Sethi, G.; Sung, B.; Aggarwal, B.B. Nuclear Factor-kB Activation: From Bench to Bedside. Exp. Biol. Med., 2008, 233, 21-31.
96. Reuben, S.C.; Gopalan, A.; Petit, D.M.; Bishayee, A. Modulation of angiogenesis by dietary phytoconstituents in the prevention and intervention of breast cancer. Mol. Nutr. Food Res., 2012, 56(1), 14-29.
97. Kunnumakkara, A.B.; Anand, P.; Aggarwal, BB. In: Drug Resistance in Cancer Cells; Kapil Mehta, Zahid.H. Siddik; Ed.; Springer Science+Business Media, LLC: New York, 2009; pp.177208.
98. Singh, N.; Nigam, M.; Ranjan, V.; Sharma, R.; Balapure, A.K.; Rath, S.K. Caspase mediated enhanced apoptotic action of cyclophosphamide and resveratrol treated MCF-7 cells. J. Pharmacol. Sci., 2009, 109(4), 473-485.
99. Harikumar, K.B.; Kunnumakkara, A.B.; Sethi, G.; Diagaradjane, P.; Anand, P.; Pandey, M.K.; Gelovani, J.; Krishnan, S.; Guha, S.; Aggarwal, B.B. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int. J. Cancer, 2010, 127(2), 257-268.
100. Li, L.; Ahmed, B.; Mehta, K.; Kurzrock, R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol. Cancer Ther., 2007, 6(4), 1276-1282.
101. Notarbatolo, M.; Poma, P.; Perri, D.; Dusonchet, L.; Cervello, M.; D'Alessandro, N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells: Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett., 2005, 224(1), 53-65.
102. Rigolio, R.; Miloso, M.; Nicolini, G.; Villa, D.; Scuteri, A.; Simone, M.; Tredici, G. Resveratrol interference with the cell cycle protects human neuroblastoma SH-SY5Y cell from paclitaxel-induced apoptosis. Neurochem. Int., 2005, 46(3), 205-211.
103. Tunali-Akbay, T.; Sehirli, O.; Ercan, F.; Sener, G. Resveratrol protects againstmethotrexate-induced hepatic injury in rats. J. Pharm. Pharm. Sci., 2010, 13(2), 303-310.
104. Kuhad, A.; Pilkhwal, S.; Sharma, S.; Tirkey, N.; Chopra, K. Effect of curcumin on inflammation and oxidative stress in cisplatin-induced experimental nephrotoxicity. J. Agric. Food Chem., 2007, 55(25), 10150-10155.
105. Alvarez, A.I.; Real, R.; PeRez, M.; Mendoza, G.; Prieto, J.G.; Merino, G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J. Pharm. Sci, 2010, 99(2), 598-617.
106. Yang, H-Y.; Zhao, L.; Yang, Z.; Zhao, Q.; Qiang, L.; Ha, J.; Li, Z-Y.; You, Q-D.; Guo, Q-L. Oroxylin A reverses multi-drug resistance of human hepatoma BEL7402/5-FU cells via downregulation of P-glycoprotein expression by inhibiting NF-kB signaling pathway. Mol. Carcinog., 2012, 51(2), 185-195.
107. Berardi R, et al. Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. Dig. Liver Dis., 2012, Doi: 10.1016/j.dld.2012.02. 006.
108. Fulda, S.; Debatin, K.M. Sensitization for anti-cancer drug induced apoptosis by the chemopreventive agent resveratrol. Oncogene, 2004, 23(40), 6702-6711.
109. Kunnumakkara, A.B.; Guha, S.; Krishnan, S.; Diagaradjane, P.; Gelovani, J.; Aggarwal, B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res., 2007, 67(8), 3853-3861.
110. Duarte, V.M.; Han, E.; Veena, M.S.; Salvado, A.; Suh, J.D.; Liang, L.J.; Faull, K.F.; Srivatsan, E.S.; Wang, M.B. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKβ protein of the NFκB pathway. Mol. Cancer Ther., 2010, 9(10), 2665-2675.
111. Lev-Ari, S.; Zinger, H.; Kazanov, D.; Yona, D.; Ben-Yosef, R.; Starr, A.; Figer, A.; Arber, N. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarcinoma cells. Biomed. Pharmacother., 2005, 59(suppl 2), S276-S280.
112. Aggarwal, B.B.; Shishodia, S.; Takada, Y.; Banerjee, S.; Newman, R.A.; Bueso-Ramos, C.E.; Price, J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res., 2005, 11(20), 7490-7498.
113. Chen, T.C.; Wang, W.; Golden, E.B.; Thomas, S.; Sivakumar, W.; Hofman, F.M.; Louie, S.G.; Schönthal, A.H. Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett., 2011, 302(2), 100-108.
114. Tang, S-N.; Fu, J.; Shankar, S.; Srivastava, R.K.; EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One, 2012, Doi: 10.1111/j.1582-4934.2012.01576.x.
115. Shervington, A.; Pawar, V.; Menon, S.; Thakkar, D.; Patel, R. The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol. Biol. Rep., 2009, 36,1181-1186.
116. Uckun, F.M.; Qazi, S.; Ozer, Z.; Garner, A.L.; Pitt, J.; Ma, H.; Janda, K.D. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br. J. Haematol., 2011, 153(6), 741-752.
117. Stearns, M.E.; Wang, M. Synergistic effects of the green tea extract epigallocatechin-3-gallate and taxane in eradication of malignant human prostate tumors. Transl. Oncol., 2011, 4(3), 147-156.
118. Sulaiman, G.M. Role of Caffeic acid phenethyl ester on mitomycin C induced clastogenesis: analysis of chromosome aberrations, micronucleus, mitotic index and adenosine deaminase activity in vivo. J. Appl. Genet., 2012, 53(2), 213-219.
119. Naus, P.J.; Henson, R.; Bleeker, G.; Wehbe, H.; Meng, F.; Patel, T. Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J. Hepatol., 2007, 46, 222-229.
120. Mohammad, R.A.; Al-Katib, A.; Aboukameel, A.; Doerge, D.R.; Sarkar, F.; Kucuk, O. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol. Cancer Ther., 2003, 2(12), 1361-1368.
121. Ündeger, U.; Aydin, S; Basaran A.A.; Basaran, N. The modulating effects of quercetin and rutin on the mitomycin C induced DNA damage. Toxicol. Lett., 2004, 151(1), 143-149.
122. Jakubowicz-Gil, J.; Paduch, R.; Piersiak, T.; Glowniak, K.; Gawron, A.; Kanderfer-Szerszen, M. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem. Pharmacol., 2005, 69, 1343-1350.
123. Banerjee, S.; Zhang, Y.; Ali, S.; Bhuiyan, M.; Wang, Z.; Chiao, P.J.; Philip, P.A.; Abbruzzese, J.; Sarkar, F.H. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res., 2005, 65(19), 9064-9072.
124. Hwang, J-T.; Ha, J.; Park, O.J. Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem. Biophys. Res. Commun., 2005, 332(2), 433-440.
125. Banerjee, S.; Zhang, Y.; Wang, Z.; Che, M.; Chiao, P.J.; Abbruzzese, J.; Sarkar, F.H. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int. J. Cancer, 2007, 120(4), 906-917.
126. Kuhar, M.; Imran, S.; Singh, N. Curcumin and quercetin combined with cisplatin to induce apoptosis in human laryngeal carcinoma Hep-2 cells through the mitochondrial pathway. Journal of Cancer Molecules, 2007, 3(4), 121-128.
127. Han, X.; Pan, J.; Ren, D.; Cheng, Y.; Fan, P.; Lou, H. Naringenin-7-O-glucoside protects against doxorubicin-induced toxicity in H9c2 cardiomyocytes by induction of endogenous antioxidant enzymes. Food Chem. Toxicol., 2008, 46(9), 3140-3146.
128. Siddique, Y.H.; Afzal, M. Antigenotoxic effect of apigenin against mitomycin C induced genotoxic damage in mice bone marrow cells. Food Chem. Toxicol., 2009, 47(3), 536-539.
129. Sharma, H.; Sen, S.; Singh, N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol. Ther., 2005, 4(9), 949-955.
130. Hormann, V.; Kumi-Diaka, J.; Durity, M.; Rathinavelu, A. Anticancer activities of genistein- topotecan combination in prostate cancer cells. J. Cell. Mol. Med., 2012, Doi: 10.1111/j.1582-4934.2012.01576.x.
131. Brechbuhl, H.M.; Kachadourian, R.; Min, E.; Chan, D.; Day, B.J. Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer 2 cell lines: The role of glutathione. Toxicol. Appl. Pharmacol., 2011, 258(1), 1-9.
132. Staedler, D.; Idrizi, E.; Kenzaoui, B.H.; Juillerat-Jeanneret, L. Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells. Cancer Chemother. Pharmacol., 2011, 68(5), 1161-1172.
133. Mazumdar, M.; Giri, S.; Giri, A. Role of quercetin on mitomycin C induced genotoxicity: Analysis of micronucleus and chromosome aberrations in vivo. Mutat. Res., 2011, 721(2), 147-152.
134. Arjumand, W.; Seth, A.; Sultana, S. Rutin attenuates cisplatin induced renal inflammation and apoptosis by reducing NFκB, TNF-α and caspase-3 expression in Wistar rats. Food Chem. Toxicol., 2011, 49(9), 2013-2021.
135. Trivedi, P.P.; Tripathi, D.N.; Jena, G.B. Hesperetin protects testicular toxicity of doxorubicin in rat: Role of NFκB, p38 and caspase-3. Food Chem. Toxicol., 2011, 49(4), 838-847.
136. Tikoo, K.; Sane, M.S.; Gupta, C. Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: Potential role of tannins in cancer chemotherapy. Toxicol. Appl. Pharmacol., 2011, 251(3), 191-200.
137. Nagaprashantha, L.D.; Vatsyayan, R.; Singhal, J.; Fast, S.; Roby, R.; Awasthi, S.; Singhal, S.S. Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem. Pharmacol., 2011, 82(9), 1100-1109.
138. Attia, S.B. Influence of resveratrol on oxidative damage in genomic DNA and apoptosis induced by cisplatin. Mutat. Res., 2011, 741(1-2), 22-31.
139. Tang, X.; Wang, H.; Fan, L.; Wu, X.; Xin, A.; Ren, H.; Wang, X.J. Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs. Free Radic. Biol. Med., 2011, 50(11), 1599-1609.
140. Patel, N.; Joseph, C.; Corcoran, G.B.; Ray, S.D. Silymarin modulates doxorubicin-induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicol. Appl. Pharmacol., 2010, 245(2), 143-152.
141. He, X.; Wang, Y.; Zhu, J.; Orloff, M.; Eng, C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signalling. Cancer Lett., 2011, 301(2), 168-176.
142. Zhang, F.Y.; Du, G.J.; Zhang, L.; Zhang, C.L.; Lu, W.L.; Liang, W. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm. Res., 2009, 26(4), 914-925.
143. Falsaperla, M.; Morgia, G.; Tartarone, A.; Ardito, R.; Romano, G. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on Standard chemotherapy using vinorelbine and estramustine phosphate. Eur. Urol., 2005, 47(4), 449-454.
144. Bayet-Robert, M.; Kwiatkowski, F.; Leheurteur, M.; Gachon, F.; Planchat, E.; Abrial, C.; Mouret-Reynier, M-A.; Durando, X.; Barthomeuf, C.; Chollet, P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther, 2010, 9(1), 8-14.
145. Nguyen, M.M.; Ahmann, F.R.; Nagle, R.B.; Hsu, C-H.; Tangrea, J.A.; Parnes, H.L.; Sokoloff, M.H.; Gretzer, M.B.; Sherry-Chow, H.H. Randomized, double-blind, placebo-controlled trial of Polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev. Res., 2012, 5(2), 290-298.
146. Choueiri, T.K.; Mekhail, T.; Hutson, T.E.; Ganapathi, R.; Kelly G.E.; Bukowski, R.M. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann. Oncol., 2006, 17(5), 860-865.
147. Ulbricht, C.E.; Chao, W. Phytochemicals in the oncology setting. Curr. Treat. Options Oncol., 2010, 11(3-4), 95-106.
148. Littman, B.H.; Di Mario, L.; Plebani, M.; Marincola, F.M. What's next in translational medicine? Clin. Sci. 2007, 112(4), 217-227.
149. Smoliga, J.M.; Vang, O.; Baur, J.A. Challenges of translating basic research into therapeutics: Resveratrol as an example. J. Gerontol. A. Biol. Sci. Med. Sci., 2011, 67(2), 158-167.
150. Fang, J-Y.; Lee, W-R.; Shen, S-C.; Huang, Y-L. Effect of liposome encapsulation of tea catechins on their accumulation in basal cell carcinomas. J. Dermatol. Sci., 2006, 42(2), 101-109.
151. Goniotaki, M.; Hatziantoniou, S.; Dimas, K.; Wagner, M.; Demetzos, C. Encapsulation of naturally occurring flavonoids into liposomes: physicochemical properties and biological activity against human cancer cell lines. J. Pharm. Pharmacol., 2004, 56(10), 1217-1224.
152. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J. Nanobiotechnology, 2007, 5, 3.
153. Siddiqui, I.A.; Adhami, V.M.; Bharali, D.J.; Hafeez, B.B.; Asim, A.; Khwaja, S.L.; Ahmad, N.; Cui, H.; Mousa, S.A.; Mukhtar, H. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res., 2009, 69(5), 1712-1716.
154. Zhang, Y.; Yang, Y.; Tang, K.; Hu, X.; Zou, G. Physicochemical characterization and antioxidant activity of quercetin-loaded chitosan nanoparticles. J. Appl. Polym. Sci., 2008, 107(2), 891-897.
155. Hung, C-F.; Lin, Y-K.; Huang, Z-R.; Fang, J-Y. Delivery of resveratrol, a red wine polyphenol, from solutions and hydrogels via the skin. Biol. Pharm. Bull., 2008, 31(5), 955-962.
156. Barreto, A.C.H.; Santiago, V.R.; Mazzetto, S.E.; Denardin, J.; Lavin, R.; Mele, G.; Ribeiro, M.; Vieira, I.; Goncalves, T.; Ricardo, N.; Fechine, P. Magnetic nanoparticles for a new drug delivery system to control quercetin releasing for cancer chemotherapy. J. Nanopart. Res., 2011. Doi: 10.1007/s11051-011-0559-9.
157. Muqbil, I.; Masood, A.; Sarkar, F.H.; Mohammad, R.M.; Azmi, A.S. Progress in nanotechnology based approaches to enhance the potential of chemopreventive agents. Cancers, 2011, 3(1), 428-445.
158. Khan, D.R. The use of nanocarriers for drug delivery in cancer therapy. J. Cancer. Sci. Ther., 2010, 2(3), 58-62.
159. Howells, L.M.; Sale, S.; Sriramareddy, N.S.; Irving, B.R.B.; Jones, D.J.L; Ottley, C.J.; Pearson, G.; Mann, C.D.; Manson, M.M.; Berry, D.P.; Gescher, A.; Steward, W.P.; Brown, K. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int. J. Cancer, 2011, 129(2), 476-486.
160. Ferenc, P.; Solár, P.; Kleban, J.; Mikes, J.; Fedorocko, P. Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells, J. Photochem. Photobiol. B., 2010, 98, 25-34.
161. Zhang, S.; Sun, D.; Hao, J.; Wei, Y-F.; Yin, L.; Liu, X. The effect of dietary soyabean isoflavones on photodynamic therapy in K562 leukemia cells. J. Photochem. Photobiol. B., 2012, 110, 28-33
162. Park, K.; Lee, J.H. Photosensitizer effect of curcumin on UVB-irradiated HaCaT cells through activation of caspase pathways. Oncol. Rep., 2007, 17(3), 537-40.